semaglutide molecular structure File:Semaglutide PDB=7ki0.png Semaglutide | Diabetes & Obesity

Topflight ensures HIPAA-compliant security measures across every platform layer and builds seamless integrations with major EHR systems to keep clinical workflows efficient and audit-ready

Changes in Bowel Habits: You may experience temporary constipation or diarrhea as the gut adjusts to the timing shift

Only 22% lean mass loss

10.7% weight loss at 42 weeks Placebo-like tolerability Only 1.5% GI-related discontinuation Improvements in waist circumference, hsCRP, and triglycerides Phase 3 planned for H2 2026 While efficacy may not yet match the most potent incretin therapies, Petrelintides favorable tolerability profile could make long-term treatment adherence a major advantage